Clicky

Viridian Therapeutics, Inc.(VRDN)

Description: Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado, with research and development operations in Waltham, Massachusetts.


Keywords: Biotechnology Biology Monoclonal Antibody Serious Diseases Thyroid Eye Disease Developmental Neuroscience Insulin Like Growth Factor 1

Home Page: www.viridiantherapeutics.com

VRDN Technical Analysis

221 Crescent Street
Waltham, MA 02453
United States
Phone: 617 272 4600


Officers

Name Title
Dr. Jonathan Violin M.B.A., Ph.D. Co-Founder, CEO, Pres & Director
Mr. Kristian Humer M.B.A. CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer
Dr. Barrett Katz CMO, M.B.A., M.D., MBA Chief Medical Officer
Dr. Eric N. Olson Ph.D. Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder & Member of the Scientific Advisory Board
Dr. Marvin H. Caruthers Ph.D. Co-Founder & Scientific Advisory Board Member
Mr. Vahe Bedian Ph.D. Co-Founder & Scientific Advisor
Ms. Carrie Melvin M.B.A. Chief Operating Officer
Dr. Rob Henderson Ph.D. Chief Scientific Officer
Mr. Todd James IRC Sr. VP of Corp. Affairs & Investor Relations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.2109
Price-to-Sales TTM: 588.21
IPO Date: 2014-06-18
Fiscal Year End: December
Full Time Employees: 50
Back to stocks